Study Condition(s): Solid Tumor, Lung Cancer
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Study Alias: JSCC
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
The results of this study are not yet available.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must have a diagnosis of cancer (confirmed by histology or cytology) that is not responsive to other treatments
- Participant must be willing to undergo tumor biopsies during the study